Our founder, Manny Villafaña, Ph.D.Sc., started Medical 21, Inc. to significantly improve the quality of life for cardiac bypass patients by eliminating the need to harvest vessels from the legs and other parts of the body.
Medical 21, Inc. is a developmental stage medical device company. We are developing and intend to commercialize and market an artificial, cellulose-based and nitinol-supported thin wall tubular graft, the MAVERICS™ Graft, to bypass lesions in the heart and other parts of the patient. Every year over 800,000 cardiac bypass surgeries are performed, using an average of 2.5 grafts per procedure.
Our revolutionary product has potential to impact these many lives and also reduce overall healthcare costs in the cardiac bypass surgery market. Manny has put together a team who collectively possess decades of experience in the successful development, manufacturing, sales, and marketing of medical products to the domestic and international healthcare markets.
The Medical 21, Inc. team has a long, proven history of creating incredible and lasting value in the medical device industry.